SC291 - Urinary obstruction in symptomatic patients undergoing renal transplantation: Proposal of a score based on urodynamic parameters

Publication date: October 2019Source: European Urology Supplements, Volume 18, Issue 9Author(s): P. Sguotti, M. Righetto, A. Calpista, F. Zattoni
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

Authors: Morabito F, Recchia AG, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, Martino M, Cutrona G, Gentile M Abstract Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases.Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversib...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
In this study, we evaluate complete blood count based inflammatory markers in hepatocellular carcinoma (HCC) to predict overall and recurrence-free survival of patients after liver transplant. Between 2001 and 2017, all HCC indicated liver transplants were retrospectively reviewed. Inclusion criteria included presence of complete blood cell counts with differential within three months prior to transplantation. Exclusion criteria included retransplantation and inadequate posttransplant followup. A total of 160 patients with HCC were included in the study. Of those, 74.4% had hepatitis C virus as the underlying cause of HCC....
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
In this study, we reviewed the current progress of the studies on the involvement of lncRNAs in SCI, with the aim of drawing attention towards their roles in this debilitating condition. PMID: 31737660 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
AbstractIt has become anticipated that regenerative medicine will extend into the field of veterinary medicine as new treatments for various disorders. Although the use of allogeneic stem cells for tissue regeneration is more attractive than that of autologous cells in emergencies, the therapeutic potential of allogeneic transplantation is often limited by allo-immune responses inducing graft rejection. Therefore, a methodology for quantifying and monitoring alloreactive T cells is necessary for evaluating allo-immune responses. The mixed lymphocyte reaction (MLR) is widely used to evaluate T cell alloreactivity. In human,...
Source: Immunogenetics - Category: Genetics & Stem Cells Source Type: research
Abstract The transplantation of neural stem cells (NSCs) has become an emerging treatment for neural degeneration. A key factor in such treatments is to manipulate NSC behaviors such as proliferation and differentiation, resulting in the eventual regulation of NSC fate. Novel bionanomaterials have shown usefulness in guiding the proliferation and differentiation of NSCs due to the materials' unique morphological and topological properties. Among the nanomaterials, graphene has drawn increasing attention for neural regeneration applications based on the material's excellent physicochemical properties, surface modif...
Source: Neural Plasticity - Category: Neurology Authors: Tags: Neural Plast Source Type: research
A highly engineered anti-CD20 antibody, obinutuzumab, enhances renal responses in lupus nephritis compared with standard immunotherapy and is well tolerated. A Phase 3 study is planned for 2020.Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Nephrology News Source Type: news
Conditions:   Hematologic Diseases;   Chronic Myeloid Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndromes;   Non Hodgkin Lymphoma;   Stem Cell Transplant Complications;   Chronic Lymphocytic Leukemia Intervention:   Other: No intervention Sponsor:   Rigshospitalet, Denmark Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Graft Versus Host Disease (GVHD) Interventions:   Biological: Alpha-1 antitrypsin (AAT);   Drug: Placebo Sponsors:   CSL Behring;   Blood and Marrow Transplant Clinical Trials Network;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Lenvatinib;   Drug: Placebo;   Drug: Immunosuppressive regimen Sponsor:   RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Glasdegib;   Drug: Gemtuzumab Ozogamicin Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Transplants | Urology & Nephrology